

Claris Lifesciences Limited

Regd. Office: Claris Corporate Headquarters, Nr. Parimal Railway Crossing, Ellisbridge, Ahmedabad – 380006
 website : www.clarislifesciences.com, e-mail : investorservices.corp@clarislifesciences.com , CIN : L85110GJ1994PLC022543

Unaudited Financial Results for the Quarter and Nine months ended September 30, 2014

(Rs.in Lacs except EPS and Shares)

Particulars	Consolidated						Standalone					
	Quarter Ended			Year to Date		Year ended	Quarter Ended			Year to Date		Year ended
	30th Sept 2014	30th June 2014	30th Sept 2013	30th Sept 2014	30th Sept. 2013	31st Dec 2013	30th Sept 2014	30th June 2014	30th Sept 2013	30th Sept 2014	30th Sept 2013	31st Dec 2013
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
PART II												
A PARTICULARS OF SHAREHOLDING												
1. Public Shareholding												
- No. of shares	21,285,801	21,285,801	25,392,554	21,285,801	25,392,554	25,392,554	21,285,801	21,285,801	25,392,554	21,285,801	25,392,554	25,392,554
- Percentage of shareholding	39.01	39.01	39.79	39.01	39.79	39.79	39.01	39.01	39.79	39.01	39.79	39.79
2. Promoters and Promoter group shareholding												
a) Pledged/Encumbered												
- Number of shares	5,928,384	5,928,384	6,834,000	5,928,384	6,834,000	-	5,928,384	5,928,384	6,834,000	5,928,384	6,834,000	-
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	17.81	17.81	17.79	17.81	17.79	-	17.81	17.81	17.79	17.81	17.79	-
- Percentage of shares (as a % of the total share capital of the Company)	10.86	10.86	10.71	10.86	10.71	-	10.86	10.86	10.71	10.86	10.71	-
b) Non-encumbered												
- Number of Shares	27,353,580	27,353,580	31,591,211	27,353,580	31,591,211	38,425,211	27,353,580	27,353,580	31,591,211	27,353,580	31,591,211	38,425,211
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	82.19	82.19	82.21	82.19	82.21	100.00	82.19	82.19	82.21	82.19	82.21	100.00
- Percentage of shares (as a % of the total share capital of the Company)	50.13	50.13	49.50	50.13	49.50	60.21	50.13	50.13	49.50	50.13	49.50	60.21
B INVESTOR COMPLAINTS												
Pending at the beginning of the quarter												1
Received during the quarter												3
Disposed of during the quarter												4
Remaining unresolved at the end of the quarter												NIL

Notes:

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 8th November 2014.
- 2 The Company has only one reportable business segment, namely, Drugs & Pharmaceuticals.
- 3 Consequent to the applicability of the Companies Act, 2013 with effect from 1st April 2014, during the quarter ended 30th June 2014, the management has reassessed the remaining useful life of assets based on internal and external technical evaluations and accordingly depreciation provision has been made for the quarter ended 30th September, 2014.
- 4 On 31st October 2014 , the Company has transferred Speciality Injectable business by way of slump sale as a "going concern" to its wholly-owned subsidiary M/s Claris Injectables Limited. The said transfer was approved by the Shareholders through postal ballot resolution dated 3rd September 2014.
- 5 With effect from 29th September 2014, a new wholly owned subsidiary (Claris Middle East FZ LLC) has been incorporated by the company in Dubai, UAE.
- 6 The figures for the previous year / period have been regrouped / rearranged wherever necessary.

For Claris Lifesciences Limited

**Place: Ahmedabad
Date: 8th November , 2014**

**Arjun Handa
Vice-Chairman & Managing Director**